

The Board of Directors' of NeuroVive Pharmaceutical AB (publ), reg. no. 556595-6538, (the "Company") resolution, subject to approval by General Meeting, to issue shares with preferential rights for existing shareholders (item 6)

The Board of Directors resolves, subject to approval by General Meeting, to increase the Company's share capital by not more than SEK 4,584,853.80 by a rights issue of not more than 91,697,076 shares with preferential rights for existing shareholders on the terms and conditions set out below.

1. The right to subscribe for shares in the rights issue shall apply to persons whom on the record date for the rights issue are registered as shareholders in the Company. Each shareholder has preferential right to subscribe for shares in relation to the number of shares previously held by the shareholder. It is noted that 126,235 shares in the Company have been subscribed and paid by exercise of warrants of series 2018:1 and that these shares will be registered and entered in to the shareholders' register kept by Euroclear Sweden AB before the record date below. All these shares will be entitled to participate in the rights issue.
2. One (1) existing share entitles to one (1) subscription right and one (1) subscription right entitles to subscription of one (1) new share.
3. The subscription price per share is SEK 1.35.
4. In the event that all new shares are not subscribed for with preferential rights the Board of Directors shall, within the limit of the maximum number of shares to be issued, resolve on allocation of shares that are not subscribed for with preferential rights. Firstly, such allotment shall be made to those who have subscribed for shares with subscription rights, irrespectively of whether they were shareholders at the record date or not, and, in the event of oversubscription, pro rata in relation to the number of subscription rights used for subscription of shares, and to the extent that this is not possible, by drawing of lots. Secondly, allotment shall be made to others who have notified their interest to subscribe for shares without subscription rights, and in the event of oversubscription, pro rata in relation to the subscribed amount, and to the extent that this is not possible, by drawing of lots. Thirdly, allocation shall be made to guarantors' pro rata in relation to guaranteed amount.
5. The record date for determining which shareholders whom are entitled to subscribe for shares with preferential right shall be Monday 21 January 2019.
6. Subscription of shares with subscription rights shall be made through payment in cash during the period from and including 23 January 2019 up to and including 6 February 2019. The Board of Directors shall have the right to extend the subscription and payment period.
7. Subscription of shares without subscription rights shall be made during the period stated in item 6 above. Such subscriptions shall be made on a separate subscription list. Payment for shares subscribed without subscription rights

shall be made in cash not later than three (3) banking days after the contract notes evidencing the allocation of shares has been sent out. The Board of Directors shall have the right to extend the subscription and payment period.

8. Subscription as concerned possible subscriptions made by guarantors shall be made on a separate subscription list no later than five (5) banking days after the end of the subscription period. Payment for such subscribed and allocated shares shall be made in cash no later than three (3) banking days after the contract notes evidencing the allocation of shares has been sent out. The Board of Directors shall have the right to extend the subscription and payment period.
9. The new shares shall entitle to dividend for the first time on the first record date for dividend that take place after the rights issue has been registered with the Swedish Companies Registration Office and the shares have been recorded in the share register kept by Euroclear Sweden AB.

Documents in accordance with Chapter 13, Section 6 in the Swedish Companies Act are attached, **Appendix 1-3**.

The CEO, or any other person appointed by the Board of Directors, shall have the right to make such minor adjustments that may be required in order to register the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.

Lund in December 2018

NeuroVive Pharmaceutical AB (publ)

The Board of Directors